Research Analysts Offer Predictions for ZVRA FY2026 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at William Blair issued their FY2026 earnings per share estimates for shares of Zevra Therapeutics in a research report issued on Wednesday, November 13th. William Blair analyst S. Corwin expects that the company will earn $0.54 per share for the year. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. The firm had revenue of $4.45 million for the quarter, compared to analysts’ expectations of $4.08 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share.

A number of other equities research analysts have also weighed in on ZVRA. JMP Securities began coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price objective for the company. Canaccord Genuity Group decreased their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a report on Monday, September 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Finally, Maxim Group increased their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Down 4.5 %

Shares of Zevra Therapeutics stock opened at $8.62 on Friday. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. Zevra Therapeutics has a 52-week low of $4.18 and a 52-week high of $9.21. The company has a market capitalization of $453.57 million, a P/E ratio of -4.38 and a beta of 1.93. The company has a 50 day moving average of $8.03 and a 200 day moving average of $6.49.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ZVRA. MetLife Investment Management LLC lifted its stake in Zevra Therapeutics by 8.1% in the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock valued at $159,000 after buying an additional 1,717 shares during the last quarter. City State Bank increased its holdings in shares of Zevra Therapeutics by 14.1% in the 3rd quarter. City State Bank now owns 16,224 shares of the company’s stock valued at $113,000 after acquiring an additional 2,000 shares during the period. The Manufacturers Life Insurance Company raised its position in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares during the last quarter. International Assets Investment Management LLC boosted its stake in shares of Zevra Therapeutics by 594.0% during the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after buying an additional 5,940 shares during the period. Finally, IFG Advisors LLC lifted its position in Zevra Therapeutics by 41.2% during the 3rd quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock worth $183,000 after acquiring an additional 7,700 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.